[开放获取]   司库奇尤单抗治疗银屑病专家共识

doi:10.35541/cjd.20240226

Abstract

Abstract: 【Abstract】 Psoriasis is an immune-mediated, chronic, inflammatory and systemic disease that can occur at any age and has a profound impact on patients′ quality of life. Interleukin-17A is a key pro-inflammatory cytokine involved in the pathogenesis of psoriasis. Secukinumab is a fully human anti-interleukin-17A monoclonal antibody. It is approved in China for the treatment of moderate‐to‐severe plaque psoriasis in patients aged 6 years or older, active psoriatic arthritis in adults and ankylosing spondylitis in adults. Since its launch, a large amount of real‐world data on the efficacy and safety has been accumulated in China. To standardize the use of secukinumab in the long‐term management of psoriasis, a systematic review of the literature on the long-term efficacy and safety of secukinumab as well as its treatment strategies and use in special populations was conducted, and an expert consensus was proposed.

Key words: Psoriasis, Secukinumab, Therapy, Disease management, Long-term management, Consensus

Working Group on “Expert consensus on clinical use of secukinumab in the treatment of psoriasis”. Expert consensus on clinical use of secukinumab in the treatment of psoriasis[J]. Chinese Journal of Dermatology, 2024, 57(12): 1079-1090.doi:10.35541/cjd.20240226

References ［92］

［1］	中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2023版）［J］. 中华皮肤科杂志, 2023,56（7）:573⁃625. doi: 10.35541/cjd.20220839.
［2］	Elmets CA, Leonardi CL, Davis D, et al. Joint AAD⁃NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities［J］. J Am Acad Dermatol, 2019,80（4）:1073⁃1113. doi: 10.1016/j.jaad.2018.11. 058.
［3］	Ghoreschi K, Balato A, Enerbäck C, et al. Therapeutics targeting the IL⁃23 and IL⁃17 pathway in psoriasis［J］. Lancet, 2021,397（10275）:754⁃766. doi: 10.1016/S0140⁃6736（21）00184⁃7.
［4］	Lynde CW, Poulin Y, Vender R, et al. Interleukin 17A: toward a new understanding of psoriasis pathogenesis［J］. J Am Acad Dermatol, 2014,71（1）:141⁃150. doi: 10.1016/j.jaad.2013.12.036.
［5］	Patel DD, Lee DM, Kolbinger F, et al. Effect of IL⁃17A blockade with secukinumab in autoimmune diseases［J］. Ann Rheum Dis, 2013,72 Suppl 2:ii116⁃ii123. doi: 10. 1136/annrheumdis⁃2012⁃202371.
［6］	Cai L, Zhang JZ, Yao X, et al. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis［J］. Chin Med J （Engl）, 2020,133（22）:2665⁃2673. doi: 10.1097/CM9.000000000 0001163.
［7］	Huang F, Sun F, Wan WG, et al. Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52⁃week, PhaseⅢ China⁃centric study, MEASURE 5［J］. Chin Med J （Engl）, 2020,133（21）:2521⁃2531. doi: 10.1097/CM9.0000000 000001099.
［8］	Mease P, van der Heijde D, Landewé R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double⁃blind, phaseⅢ FUTURE 5 study［J］. Ann Rheum Dis, 2018,77（6）:890⁃897. doi: 10.1136/annrheumdis⁃2017⁃212687.
［9］	Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique［J］. J Adv Nurs, 2000,32（4）:1008⁃1015.
［10］	WHO. Global report on psoriasis［M/OL］. Switzerland: WHO Press, 2016. ［2024⁃04⁃19］. https://iris.who.int/bitstream/handle/10665/204417/9789241565189_eng.pdf?sequence=1.
［11］	Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council［J］. J Am Acad Dermatol, 2020,82（1）:117⁃122. doi: 10.1016/j.jaad. 2019.08.026.
［12］	中华医学会皮肤性病学分会银屑病专业委员会. 银屑病生物制剂达标治疗专家共识［J］. 中华皮肤科杂志, 2023,56（3）:191⁃203. doi: 10.35541/cjd.20220652.
［13］	de la Cueva Dobao P, Notario J, Ferrándiz C, et al. Expert consensus on the persistence of biological treatments in moderate⁃to⁃severe psoriasis［J］. J Eur Acad Dermatol Venereol, 2019,33（7）:1214⁃1223. doi: 10.1111/jdv.15600.
［14］	Foley P, Gebauer K, Sullivan J, et al. Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies ⁃ Adult patients［J］. Australas J Dermatol, 2023,64（4）:476⁃487. doi: 10.1111/ajd.14138.
［15］	Yeung J, Bourcier M, Gooderham MJ, et al. Management of moderate⁃to⁃severe plaque psoriasis with biologics: a treat⁃to⁃target position paper［J］. Dermatol Ther, 2022,35（10）:e15777. doi: 10.1111/dth.15777.
［16］	McInnes IB, Gravallese EM. Immune⁃mediated inflammatory disease therapeutics: past, present and future［J］. Nat Rev Immunol, 2021,21（10）:680⁃686. doi: 10.1038/s41577⁃021⁃00603⁃1.
［17］	Bissonnette R, Luger T, Thaçi D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate⁃to⁃severe psoriasis through 5 years of treatment （SCULPTURE Extension Study）［J］. J Eur Acad Dermatol Venereol, 2018,32（9）:1507⁃1514. doi: 10.1111/jdv.14878.
［18］	Chen K, Wang G, Jin H, et al. Clinic characteristics of psoriasis in China: a nationwide survey in over 12000 patients［J］. Oncotarget, 2017,8（28）:46381⁃46389. doi: 10.18632/oncotarget. 18453.
［19］	Ding Y, Li W, Guan X, et al. Treatment outcomes of secukinumab in adult patients with moderate⁃to⁃severe plaque psoriasis in China: a real⁃world multicenter retrospective study［J］. Clin Transl Sci, 2023,16（10）:1803⁃1814. doi: 10.1111/cts. 13583.
［20］	Huang H, Cai ML, Hong XJ, et al. Real⁃world data on the use of secukinumab as treatment for moderate⁃to⁃severe psoriasis in Chinese patients［J］. Eur J Dermatol, 2020,30（5）:554⁃560. doi: 10.1684/ejd.2020.3878.
［21］	Zhao Y, Cai L, Liu XY, et al. Efficacy and safety of secukinumab in Chinese patients with moderate⁃to⁃severe plaque psoriasis: a real⁃life cohort study［J］. Chin Med J （Engl）, 2021,134（11）:1324⁃1328. doi: 10.1097/CM9.0000000000001510.
［22］	Zhou J, Yuan Y, Liu Y, et al. Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real⁃world practice［J］. Exp Dermatol, 2024,33（1）:e14890. doi: 10.1111/exd.14890.
［23］	Mu ZL,Wang XH,Lin BJ, et a. Effectiveness of secukinumab among Chinese adult patients with moderate plaque psoriasis: interim results from the UNMASK2 study［C/OL］//The 32nd European Academy of Dermatology and Venereology （EADV） Congress, Berlin, 2023［2024⁃04⁃19］.https://eadv.org/wp⁃content/uploads/scientific⁃abstracts/EADV⁃congress⁃2023/Psoriasis.pdf.
［24］	Augustin M, Sator PG, von Kiedrowski R, et al. Secukinumab demonstrated sustained retention, effectiveness and safety in a real⁃world setting in patients with moderate⁃to⁃severe plaque psoriasis: long⁃term results from an interim analysis of the SERENA study［J］. J Eur Acad Dermatol Venereol, 2022,36（10）:1796⁃1804. doi: 10.1111/jdv.18329.
［25］	Galluzzo M, D'Adamio S, Silvaggio D, et al. In which patients the best efficacy of secukinumab? Update of a real⁃life analysis after 136 weeks of treatment with secukinumab in moderate⁃to⁃severe plaque psoriasis［J］. Expert Opin Biol Ther, 2020,20（2）:173⁃182. doi: 10. 1080/14712598.2020.1708897.
［26］	Sotiriou E, Bakirtzi K, Vakirlis E, et al. Long⁃term drug survival of secukinumab in real life in the era of novel biologics: a 5⁃year, retrospective study, including difficult⁃to⁃treat areas［J］. J Eur Acad Dermatol Venereol, 2022,36（8）:e626⁃e627. doi: 10.1111/jdv.18087.
［27］	Foley P, Spelman L, Murrell DF, et al. Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: results from the HOPE study［J］. Australas J Dermatol, 2022,63（3）:312⁃320. doi: 10.1111/ajd.13893.
［28］	Wang Y, Wang X, Yu Y, et al. A retrospective study to assess the efficacy, safety, and drug survival of secukinumab in plaque psoriasis patients in China［J］. Dermatol Ther, 2021,34（5）:e15081. doi: 10.1111/dth. 15081.
［29］	Reich K, Körber A, Mrowietz U, et al. Secukinumab 2⁃weekly vs. 4⁃weekly dosing in patients with plaque⁃type psoriasis: results from the randomized GAIN study［J］. Br J Dermatol, 2021,184（5）:849⁃856. doi: 10.1111/bjd.19398.
［30］	Reich K, Puig L, Szepietowski JC, et al. Secukinumab dosing optimization in patients with moderate⁃to⁃severe plaque psoriasis: results from the randomized, open⁃label OPTIMISE study［J］. Br J Dermatol, 2020,182（2）:304⁃315. doi: 10.1111/bjd.18143.
［31］	Mrowietz U, Leonardi CL, Girolomoni G, et al. Secukinumab retreatment⁃as⁃needed versus fixed⁃interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double⁃blind, noninferiority trial （SCULPTURE）［J］. J Am Acad Dermatol, 2015,73（1）:27⁃36. doi: 10.1016/j.jaad. 2015. 04.011.
［32］	Eyerich K, Krueger J, Stahle M, et al. An international Delphi consensus to define a clinically appropriate definition of disease modification for plaque psoriasis［J］. J Eur Acad Dermatol Venereol, 2024,38（5）:e424⁃e427. doi: 10.1111/jdv.19652.
［33］	Kim J, Lee J, Hawkes JE, et al. Secukinumab improves mild⁃to⁃moderate psoriasis: a randomized, placebo⁃controlled exploratory clinical trial［J］. J Am Acad Dermatol, 2023,88（2）:428⁃430. doi: 10.1016/j.jaad. 2022.04.060.
［34］	Conrad C, Gaulis S, Bier K, et al. 828 Early intervention with secukinumab may affect the establishment of tissue memory in psoriasis: results from a DNA methylation analysis ［J］. J Invest Dermatol, 2023,143（5）:S142. doi: 10.1016/j.jid.2023.03.838.
［35］	Iversen L, Conrad C, Eidsmo L, et al. Secukinumab demonstrates superiority over narrow⁃band ultraviolet B phototherapy in new⁃onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn study［J］. J Eur Acad Dermatol Venereol, 2023,37（5）:1004⁃1016. doi: 10.1111/jdv.18846.
［36］	Kampylafka E, Simon D, d'Oliveira I, et al. Disease interception with interleukin⁃17 inhibition in high⁃risk psoriasis patients with subclinical joint inflammation⁃data from the prospective IVEPSA study［J］. Arthritis Res Ther, 2019,21（1）:178. doi: 10.1186/s13075⁃019⁃1957⁃0.
［37］	Lebwohl M, Iversen L, Eidsmo L, et al. Investigation of plaque psoriasis relapse after secukinumab withdrawal in patients from two phaseⅢ studies［J］. Clin Exp Dermatol, 2024,49（8）:793⁃800. doi: 10.1093/ced/llad329.
［38］	Griffiths C, Armstrong AW, Gudjonsson JE, et al. Psoriasis［J］. Lancet, 2021,397（10281）:1301⁃1315. doi: 10.1016/S0140⁃6736（20）32549⁃6.
［39］	Galluzzo M, Talamonti M, Atzori L, et al. Secukinumab for the treatment of palmoplantar psoriasis: a 2⁃year, multicenter, real⁃life observational study［J］. Expert Opin Biol Ther, 2022,22（4）:547⁃554. doi: 10.1080/14712598.2022.2029841.
［40］	Gottlieb AB, Kubanov A, van Doorn M, et al. Sustained efficacy of secukinumab in patients with moderate⁃to⁃severe palmoplantar psoriasis: 2•5⁃year results from GESTURE, a randomized, double⁃blind, placebo⁃controlled trial［J］. Br J Dermatol, 2020,182（4）:889⁃899. doi: 10.1111/bjd.18331.
［41］	Gottlieb A, Sullivan J, van Doorn M, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial［J］. J Am Acad Dermatol, 2017,76（1）:70⁃80. doi: 10. 1016/j.jaad.2016.07.058.
［42］	王晓华, 慕彰磊, 林秉奖, 等. 司库奇尤单抗治疗特殊部位受累银屑病患者的短期疗效: UNMASK2真实世界研究的16周中期分析结果［C］//2023全国中西医结合皮肤性病学术会议,昆明, 2023［2024⁃04⁃19］. doi: 10.26914/c.cnkihy.2023.009521.
［43］	Nash P, Mease PJ, Kirkham B, et al. Secukinumab provides sustained improvement in nail psoriasis, signs and symptoms of psoriatic arthritis and low rate of radiographic progression in patients with concomitant nail involvement: 2⁃year results from the PhaseⅢ FUTURE 5 study［J］. Clin Exp Rheumatol, 2022,40（5）:952⁃959. doi: 10.55563/clinexprheumatol/3nuz51.
［44］	Reich K, Sullivan J, Arenberger P, et al. Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5⁃year results from the randomized placebo⁃controlled TRANSFIGURE study［J］. Br J Dermatol, 2021,184（3）:425⁃436. doi: 10.1111/bjd. 19262.
［45］	Reich K, Sullivan J, Arenberger P, et al. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32⁃week results from the randomized placebo⁃controlled TRANSFIGURE trial［J］. Br J Dermatol, 2019,181（5）:954⁃966. doi: 10.1111/bjd.17351.
［46］	Piaserico S, Riedl E, Pavlovsky L, et al. Comparative effectiveness of biologics for patients with moderate⁃to⁃severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes （PSoHO）［J］. Front Med （Lausanne）, 2023,10:1185523. doi: 10.3389/fmed.2023.1185523.
［47］	Bagel J, Duffin KC, Moore A, et al. The effect of secukinumab on moderate⁃to⁃severe scalp psoriasis: results of a 24⁃week, randomized, double⁃blind, placebo⁃controlled phase 3b study［J］. J Am Acad Dermatol, 2017,77（4）:667⁃674. doi: 10.1016/j.jaad.2017.05.033.
［48］	Feldman SR, Green L, Kimball AB, et al. Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate⁃to⁃severe scalp psoriasis［J］. J Dermatolog Treat, 2017,28（8）:716⁃721. doi: 10.1080/09546634.2017.1329502.
［49］	Baraliakos X, Gossec L, Pournara E, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double⁃blind, randomised, phase 3 MAXIMISE trial［J］. Ann Rheum Dis, 2021,80（5）:582⁃590. doi: 10.1136/annrheumdis⁃ 2020⁃218808.
［50］	McInnes IB, Behrens F, Mease PJ, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis （EXCEED）: a double⁃blind, parallel⁃group, randomised, active⁃controlled, phase 3b trial［J］. Lancet, 2020,395（10235）:1496⁃1505. doi: 10.1016/S0140⁃6736（20）30564⁃X.
［51］	McInnes IB, Mease PJ, Kivitz AJ, et al. Long⁃term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5⁃year （end⁃of⁃study） results from the phase 3 FUTURE 2 study［J］. Lancet Rheumatol, 2020,2（4）:e227⁃e235. doi: 10.1016/S2665⁃9913（20）30036⁃9.
［52］	McInnes IB, Mease PJ, Ritchlin CT, et al. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study［J］. Rheumatology （Oxford）, 2017,56（11）:1993⁃2003. doi: 10.1093/rheumatology/kex301.
［53］	Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis （GRAPPA）: updated treatment recommendations for psoriatic arthritis 2021［J］. Nat Rev Rheumatol, 2022,18（8）:465⁃479. doi: 10.1038/s41584⁃022⁃00798⁃0.
［54］	苏茵, 王彩虹, 高晋芳, 等. 银屑病关节炎诊疗规范［J］. 中华内科杂志, 2022,61（8）:883⁃892. doi: 10.3760/cma.j.cn112138⁃20220103⁃00003.
［55］	Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52⁃week analysis from phaseⅢ open⁃label multicenter Japanese study［J］. J Dermatol, 2016,43（9）:1011⁃1017. doi: 10.1111/1346⁃8138.13306.
［56］	Mrowietz U, Bachelez H, Burden AD, et al. Secukinumab for moderate⁃to⁃severe palmoplantar pustular psoriasis: results of the 2PRECISE study［J］. J Am Acad Dermatol, 2019,80（5）:1344⁃1352. doi: 10.1016/j.jaad.2019.01.066.
［57］	Ruan SF, Zhang LL, Liu Z, et al. Real⁃world data on the clinical use of secukinumab in pediatric generalized pustular psoriasis: a 48⁃week retrospective study［J］. J Am Acad Dermatol, 2023,88（1）:243⁃246. doi: 10.1016/j.jaad.2022.04.064.
［58］	周健, 俞晨, 王刚. 司库奇尤单抗治疗13例难治性局限性脓疱型银屑病的临床疗效与安全性观察［J］. 中华皮肤科杂志, 2023,56（3）:247⁃251. doi: 10.35541/cjd.20220295.
［59］	Menter A, Strober BE, Kaplan DH, et al. Joint AAD⁃NPF guidelines of care for the management and treatment of psoriasis with biologics［J］. J Am Acad Dermatol, 2019,80（4）:1029⁃1072. doi: 10.1016/j.jaad.2018.11.057.
［60］	Amatore F, Villani AP, Tauber M, et al. French guidelines on the use of systemic treatments for moderate⁃to⁃severe psoriasis in adults［J］. J Eur Acad Dermatol Venereol, 2019,33（3）:464⁃483. doi: 10.1111/jdv.15340.
［61］	Damiani G, Pacifico A, Russo F, et al. Use of secukinumab in a cohort of erythrodermic psoriatic patients: a pilot study［J］. J Clin Med, 2019,8（6）:770. doi: 10.3390/jcm8060770.
［62］	Weng HJ, Wang TS, Tsai TF. Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series［J］. Br J Dermatol, 2018,178（6）:1439⁃1440. doi: 10.1111/bjd.16252.
［63］	张婷婷, 朱凤仪, 杨梅, 等. 司库奇尤单抗治疗红皮病型银屑病7例的临床疗效及安全性观察［J］. 中华皮肤科杂志, 2022,55（10）:892⁃894. doi: 10.35541/cjd.20210644.
［64］	U.S. Food and Drug Administration. COSENTYX® （secukinumab） injection, for subcutaneous or intravenous use Initial U.S. Approval 2015［EB/OL］. ［2024⁃04⁃19］. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761349s000lbl.pdf
［65］	Bardowska K, Krajewski PK, Tyczyńska K, et al. Safety evaluation of secukinumab in pediatric patients with plaque psoriasis［J］. Expert Opin Drug Saf, 2022,21（7）:867⁃872. doi: 10.1080/14740338.2022.2073349.
［66］	Bodemer C, Kaszuba A, Kingo K, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52⁃week results from a phase 3 double⁃blind randomized, controlled trial［J］. J Eur Acad Dermatol Venereol, 2021,35（4）:938⁃947. doi: 10.1111/jdv.17002.
［67］	Magnolo N, Kingo K, Laquer V, et al. Efficacy of secukinumab across subgroups and overall safety in pediatric patients with moderate to severe plaque psoriasis: week 52 results from a phaseⅢ randomized study［J］. Paediatr Drugs, 2022,24（4）:377⁃387. doi: 10. 1007/s40272⁃022⁃00507⁃0.
［68］	Zheng YX, Ye LR, Yan BX, et al. Biologics for psoriasis patients under 18 years of age: real⁃world evidence from the Chinese psoriasis real world evidence research group［J］. Front Med （Lausanne）, 2022,9:1009991. doi: 10. 3389/fmed.2022.1009991.
［69］	谢辉, 牛美丽, 王新慧, 等. 司库奇尤单抗治疗儿童银屑病六例疗效评价［J］. 中国麻风皮肤病杂志, 2021,37（3）:157⁃159,162. doi: 10.12144/zgmfskin202103157.
［70］	Phan C, Beneton N, Delaunay J, et al. Effectiveness and safety of anti⁃interleukin⁃17 therapies in elderly patients with psoriasis［J］. Acta Derm Venereol, 2020,100（18）:adv00316. doi: 10.2340/00015555⁃3678.
［71］	Körber A, Papavassilis C, Bhosekar V, et al. Efficacy and safety of secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phaseⅢ studies［J］. Drugs Aging, 2018,35（2）:135⁃144. doi: 10.1007/s40266⁃018⁃0520⁃z.
［72］	Megna M, Camela E, Cinelli E, et al. Real⁃life efficacy and safety of secukinumab in elderly patients with psoriasis over a 2⁃year period［J］. Clin Exp Dermatol, 2020,45（7）:848⁃852. doi: 10. 1111/ced.14258.
［73］	European Medicines Agency. Cosentyx: EPAR ⁃ Product Information. 2023［EB/OL］. ［2024⁃04⁃19］. https://www.ema.europa.eu/en/documents/product⁃information/cosentyx⁃epar⁃product⁃information_en.pdf
［74］	Elewski BE, Baddley JW, Deodhar AA, et al. Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis［J］. JAMA Dermatol, 2021,157（1）:43⁃51. doi: 10.1001/jamadermatol. 2020. 3257.
［75］	Shu D, Zhang Z, Zhou EY, et al. Is chemoprophylaxis necessary for all latent tuberculosis infection patients receiving IL⁃17 inhibitors? A cohort study［J］. Dermatol Ther, 2020,33（6）:e14512. doi: 10.1111/dth.14512.
［76］	中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物制剂治疗指南（2021）［J］. 中华皮肤科杂志, 2021,54（12）:1033⁃1047. doi: 10.35541/cjd. 20210643.
［77］	Lebwohl M, Deodhar A, Griffiths C, et al. The risk of malignancy in patients with secukinumab⁃treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow⁃up［J］. Br J Dermatol, 2021,185（5）:935⁃944. doi: 10.1111/bjd. 20136.
［78］	van de Kerkhof P. The risk of malignancy in patients with secukinumab⁃treated psoriasis, psoriatic arthritis and ankylosing spondylitis［J］. Br J Dermatol, 2021,185（5）:879. doi: 10.1111/bjd.20624.
［79］	Garshick MS, Ward NL, Krueger JG, et al. Cardiovascular risk in patients with psoriasis: JACC review topic of the week［J］. J Am Coll Cardiol, 2021,77（13）:1670⁃1680. doi: 10.1016/j.jacc.2021. 02.009.
［80］	Elnabawi YA, Dey AK, Goyal A, et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study［J］. Cardiovasc Res, 2019,115（4）:721⁃728. doi: 10.1093/cvr/cvz009.
［81］	Makavos G, Ikonomidis I, Andreadou I, et al. Effects of interleukin 17A inhibition on myocardial deformation and vascular function in psoriasis［J］. Can J Cardiol, 2020,36（1）:100⁃111. doi: 10.1016/j.cjca.2019.06.021.
［82］	Merola JF, McInnes IB, Deodhar AA, et al. Effect of secukinumab on traditional cardiovascular risk factors and inflammatory biomarkers: post hoc analyses of pooled data across three indications［J］. Rheumatol Ther, 2022,9（3）:935⁃955. doi: 10.1007/s40744⁃022⁃00434⁃z.
［83］	von Stebut E, Reich K, Thaçi D, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks［J］. J Invest Dermatol, 2019,139（5）:1054⁃1062. doi: 10.1016/j.jid.2018.10. 042.
［84］	Richard MA, Lacour JP, Konstantinou MP, et al. Secukinumab efficacy in reducing the severity and the psychosocial impact of moderate⁃to⁃severe psoriasis as assessed by the Simplified Psoriasis Index: results from the IPSI⁃PSO study［J］. J Eur Acad Dermatol Venereol, 2021,35（3）:677⁃684. doi: 10.1111/jdv.16893.
［85］	Augustin M, Reich K, Yamauchi P, et al. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial［J］. Br J Dermatol, 2022,186（6）:942⁃954. doi: 10.1111/bjd.20971.
［86］	Fassio A, Gatti D, Gisondi P, et al. Effects of secukinumab on serum adipocytokines: preliminary data［J］. Reumatismo, 2017,69（3）:105⁃110. doi: 10.4081/reumatismo.2017.953.
［87］	Gerdes S, Pinter A, Papavassilis C, et al. Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients［J］. J Eur Acad Dermatol Venereol, 2020,34（3）:533⁃541. doi: 10.1111/jdv.16004.
［88］	Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis⁃⁃results of two phase 3 trials［J］. N Engl J Med, 2014,371（4）:326⁃338. doi: 10.1056/NEJMoa1314258.
［89］	Zhang S, Cai L, Zhang H, et al. Effects of adalimumab and secukinumab on comorbidities associated with metabolism in patients with plaque psoriasis［J］. Chin Med J （Engl）, 2022,135（18）:2248⁃2250. doi: 10.1097/CM9.0000000000002143.
［90］	Zhao Z, Cai L, Zhang S, et al. Effects of secukinumab and adalimumab on serum uric acid level in patients with plaque psoriasis［J］. Chin Med J （Engl）, 2022,135（12）:1438⁃1443. doi: 10.1097/CM9.0000000000002130.
［91］	van de Kerkhof PC, Griffiths CE, Reich K, et al. Secukinumab long⁃term safety experience: a pooled analysis of 10 phaseⅡ and Ⅲ clinical studies in patients with moderate to severe plaque psoriasis［J］. J Am Acad Dermatol, 2016,75（1）:83⁃98. doi: 10.1016/j.jaad. 2016. 03.024.
［92］	Gottlieb AB, Deodhar A, Mcinnes IB, et al. Long⁃term safety of secukinumab over five years in patients with moderate⁃to⁃severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post⁃marketing surveillance data［J］. Acta Derm Venereol, 2022,102:adv00698. doi: 10.2340/actadv.v102.563.

[1]	Xiang Xi, Zhang Lingyan, Zhong Lin, Gao Yi, Qiu Li. Multimodal ultrasound manifestations of port-wine stains and their application in efficacy assessment of photodynamic therapy [J]. Chinese Journal of Dermatology, 2024, 57(9): 801-806.
[2]	Qiao Jiaxi, Xia Ping, Chen Liuqing. Analysis of dermoscopic and reflectance confocal microscopic features of psoriatic lesions before and after treatment with secukinumab [J]. Chinese Journal of Dermatology, 2024, 57(9): 825-829.
[3]	Combination of Traditional and Western Medicine Dermatology, Chinese Society of Dermatology, China Dermatologist Association. Expert consensus on the application of reflectance confocal microscopy in common melanocytic skin tumors（2024） [J]. Chinese Journal of Dermatology, 2024, 57(9): 775-784.
[4]	Wang Ruixia, Qu Yanlei, Ai Wenjin, Yan Lin, Qu Caijie, Shi Tongxin. A case of nonbullous neutrophilic lupus erythematosus [J]. Chinese Journal of Dermatology, 2024, 57(9): 832-834.
[5]	Dou Jinfa, Wang Jianbo, Zhang Shuai, Li Jianguo, Liu Hongwei, Zhang Shoumin. Analysis of changes in disease status and their influencing factors in patients with moderate to severe plaque psoriasis receiving biologic therapy during the coronavirus disease 2019 pandemic: a single-center cross-sectional study [J]. Chinese Journal of Dermatology, 2024, 57(8): 739-742.
[6]	Lin Ziyuan, Pang Tianyi, Wu Jingwen, Jin Hui, . Role of polycyclic aromatic hydrocarbons in the occurrence and development of inflammatory skin diseases [J]. Chinese Journal of Dermatology, 2024, 57(8): 765-769.
[7]	Wei-Qi REN Ya-Ru ZOU Min PAN. Risk factors for secondary infection in patients with bullous pemphigoid [J]. Chinese Journal of Dermatology, 2024, 57(8): 770-772.
[8]	Luo Li, Zhang Bona, Wu Wei, Tang Wenjing, Li Yuehua, Liu Xiaoli, Ma Yanan, Li Cuicui, Qi Mengyan, Sun Ni, Shi Qiong. Efficacy and safety of 308-nm excimer laser and 308-nm excimer lamp in the treatment of 194 children with vitiligo: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(8): 721-727.
[9]	Chen Haotian, Liu Lian, Zhang Ting, Liu Qingfeng, Li Xiaoxue, Diao Ping, Jiang Xian. Port-wine stains: mechanisms underlying the development and progression [J]. Chinese Journal of Dermatology, 2024, 57(7): 661-664.
[10]	Diao Ping, Han Chenglong, Liu Lian, Zhou Hui, Li Erlong, Jiang Xian. Efficacy and influencing factors of hematoporphyrin monomethyl ether-mediated photodynamic therapy in the treatment of adult patients with port-wine stains: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(7): 595-600.
[11]	Zhang Sheng, Wang Xiuwei, Chen Jianyou, Deng Wei, Zhang Haihua, Zhang Gaolei, Liu Xiaoyan, Su Wei. Efficacy of hematoporphyrin monomethyl ether-mediated photodynamic therapy in the treatment of facial port-wine stains in 15 children with Sturge-Weber syndrome [J]. Chinese Journal of Dermatology, 2024, 57(7): 616-622.
[12]	Jiang Xian, Liu Lian, Zhang Ting. Treatment of port-wine stains: current status and prospects [J]. Chinese Journal of Dermatology, 2024, 57(7): 590-594.
[13]	The Consensus Development Expert Group of Hematoporphyrin Monomethyl Ether-mediated Photodynamic Therapy for Treating Port-wine Stains. Expert consensus on hematoporphyrin monomethyl ether-mediated photodynamic therapy for treating port-wine stains （2024） [J]. Chinese Journal of Dermatology, 2024, 57(7): 581-589.
[14]	Yang Aimin, Cheng Jiangwei, Huang Jiacheng, Cen Ying, Chen Junjie. Treatment of Merkel cell carcinoma [J]. Chinese Journal of Dermatology, 2024, 57(7): 665-667.
[15]	Sui Changlin, Chang Xiao, Zhao Qi, Zhu Wei. Psoriasis induced by anti-tumor targeted therapy and immunotherapy [J]. Chinese Journal of Dermatology, 2024, 57(6): 570-574.

Expert consensus on clinical use of secukinumab in the treatment of psoriasis

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［92］

Related Articles 15

Metrics

Comments

Recommended 10